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Abstract
Background In rare diseases such as ryanodine receptor 1-related myopathies (RYR1-RM), health-related quality of life 
(HRQoL) measures are critically important so clinicians and researchers can better understand what symptoms are most 
important to participants, with the ultimate goal of finding tangible solutions for them.
Objectives The main objective of this study was to characterize symptoms in individuals with RYR1-RM to inform future 
research. A secondary objective of this study was to analyze positive and negative sentiments regarding symptoms and treat-
ment effects post N-acetylcysteine (NAC) administration in individuals with RYR1-RM.
Methods The study used a mixed-methods design applying methodological triangulation. Qualitative data were collected via 
semi-structured interviews at three visits to characterize symptoms in individuals with RYR1-RM and to analyze treatment 
effects. Qualitative data were then transformed into quantitative results to measure the frequency with which each symptom 
was mentioned by participants.
Results A total of 12 symptoms were identified as areas of interest to participants with RYR1-RM, highlighting fatigue and 
weakness as key symptoms. Data transformation categorized more than 1000 citations, reporting a greater number of posi-
tive comments for postintervention interviews than for baseline and preintervention visits and that NAC group participants 
stated more positive comments regarding treatment effect than did the placebo group.
Conclusions We present a comprehensive characterization of symptoms in RYR1-RM and how those symptoms influence 
HRQoL. Furthermore, the introduction of mixed methods may be a valuable way to better understand patient-centered data 
in rare diseases to support affected individuals in coping with their symptoms.
Key Points for Decision Makers 
Symptoms of individuals with ryanodine receptor 
1-related myopathies (RYR1-RM), a rare disease, were 
systematically characterized from a patient perspective 
to inform and support affected individuals, family mem-
bers, and healthcare providers.
A specific research design was applied to better under-
stand patient-centered data to promote its application in 
future studies of RYR1-RM.
This approach meets US FDA guidance on the inclusion 
of affected individuals’ feedback in developing patient-
reported outcome measures and clinical trials for drug 
development.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 1-020-00418 -7) contains 
supplementary material, which is available to authorized users.
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1 Introduction
In recent years, a burgeoning transition has taken place 
from traditional clinical research methods that are centered 
on study goals to the inclusion of input from affected indi-
viduals in the research process. This change emphasizes a 
direct approach to measuring how affected individuals feel 
and function and highlights the value of patient-centered 
data, not only for developing patient-reported outcome 
(PRO) measures [1] but also for drug development [2].
Patient-centered data and research are becoming 
increasingly recognized and are informing regulatory deci-
sions, health policies, research design, and research cost 
analyses [3]. They also provide important insights into 
affected individuals’ experience as it relates to their func-
tional outcomes, responses to disease symptoms or treat-
ment side effects, and/or an overall assessment of quality 
of life (QoL). Health-related QoL (HRQoL) looks at these 
facets through the lens of disease and medical care.
Where treatments have not yet been discovered, HRQoL 
measures are particularly important so clinicians and 
researchers can better understand what disease effects 
are most important to participants, with the ultimate goal 
of finding tangible solutions for them [4, 5]. Addition-
ally, in smaller populations such as rare diseases, PRO 
trial endpoints become more critical in targeting the most 
significant symptoms [6]. Therefore, selecting appropri-
ate PRO measures offers a unique added value not only 
to understanding the impact of medical conditions and 
treatments from the affected individuals’ perspective but 
also to ensure any impact of a trial intervention would 
be comprehensively assessed and meaningful, support-
ing trial interpretations. This requires the development 
of specific instruments to address the effects of rare dis-
eases in their limited population rather than using existing 
generic HRQoL measures. Results from our research will 
enhance the development of these tools for neuromuscular 
disorders.
Overall, PROs enrich data to improve future clinical 
trial methods, study design, participant selection, and bio-
medical outcomes [7, 8]. Furthermore, PROs help enable 
positive research experiences that enhance future recruit-
ment, another challenge in rare disease [9–11]. However, 
quantitative PRO data have known limitations in neuro-
muscular diseases, such as the “disability paradox” (i.e., 
affected individuals with neuromuscular disease self-
report a high QoL on HRQoL scales, whereas their family, 
caregivers, or external observers report them as having a 
low QoL) [12–15]. It is therefore important to add quali-
tative analyses to studies to better understand this issue.
Mixed-methods analysis, which combines quanti-
tative and qualitative approaches to provide a more 
comprehensive understanding of data, has been proposed 
as the best practice to address patient-centered data in rare 
diseases since this methodology allows the use of data 
from small sample sizes [16, 17]. Recent guidance by the 
US FDA have also provided industry recommendations 
for ensuring patient perspectives are captured in clinical 
research [18]. Therefore, we explored the application of 
mixed methods to a study of individuals affected with 
ryanodine receptor 1-related myopathies (RYR1-RM).
RYR1-RM are caused by pathogenic variants in the RYR1 
gene, which is highly intolerant to change and encodes the 
major calcium channel in skeletal muscle [19–21]. RYR1-
RM comprise the most common form of congenital myo-
pathy, with a pediatric incidence of > 1:90,000 in the USA 
[21–23]. Common RYR1-RM clinical manifestations include 
proximal/axial muscle weakness, delayed motor milestones, 
impaired mobility, pain, and fatigue [23–29]. Although 
affected individuals report fatigue as one of the more perva-
sive symptoms [25], these symptoms vary greatly in severity. 
Currently there is no FDA-approved treatment for RYR1-RM 
[20]. For this reason, it was necessary to perform additional 
research to characterize symptoms, especially regarding 
treatment effects and symptom alleviation.
The application of mixed methods in RYR1-RM research 
to incorporate participants’ perspectives on their symptoms 
may inform future PRO measures and maximize our under-
standing of RYR1 symptoms. Both qualitative (exploratory 
primary endpoint) and quantitative (secondary endpoint) 
PRO methods were employed during a combined natural 
history study and clinical trial of N-acetylcysteine (NAC) 
(NCT02362425) to facilitate an understanding of the 
affected individuals’ point of view regarding their symptoms 
and to analyze treatment effects.
2  Materials and Methods
2.1  Standard Protocol Approvals, Registrations, 
and Patient Consents
The RYR1 NAC clinical trial consisted of two components: 
a prospective natural history assessment and a parallel-
group, randomized, double-blind, placebo-controlled trial. 
The trial incorporated a comparison of quantitative and 
qualitative PRO data to identify symptoms and subjective 
improvements post NAC treatment  (Harmonic®, BioAdvan-
tex Pharma Inc., Toronto, ON, Canada). Given the potential 
therapeutic efficacy of NAC for RYR1-RM [30–32], NAC 
or placebo were administered orally for 6 months (adult 
dose 2700 mg/day; pediatric dose 30 mg/kg/day). At the 
conclusion of the trial, no difference in the primary out-
come measure for oxidative stress was observed. Results 
from the 6-minute walk test were 24 m longer on average in 
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the NAC arm, but this did not reach statistical significance 
[20]. The study was conducted at the National Institutes of 
Health (NIH) Clinical Center, Bethesda, MD, USA, between 
2015 and 2017. This was the first clinical trial conducted 
in this patient population. The clinical trial is registered in 
the US National Library of Medicine (NCT02362425). All 
procedures were approved by the NIH combined neurosci-
ence institutional review board, and an independent moni-
toring committee was established to oversee trial safety. 
All participants and parents of participants age < 18 years 
provided written informed consent, according to the Dec-
laration of Helsinki, before enrollment. Assent was also 
obtained for those aged < 18 years. The total study duration 
was 18 months and consisted of a 6-month natural history 
assessment, followed by a 6-month intervention phase, and 
a follow-up phone call at 18 months. Participants attended 
three study visits at the NIH: baseline, preintervention, and 
postintervention. Randomization was performed at the end 
of the second visit. For more information regarding the clini-
cal trial, see Todd et al. [20].
2.2  Study Design
An exploratory sequential mixed-methods design with meth-
odological triangulation was employed, QUAL → (quan) 
[33, 34]. The mixed-methods approach was recently recom-
mended by the FDA to incorporate patients’ perspectives in 
clinical research [18]. Qualitative data were collected via 
semistructured interviews at each visit to characterize symp-
toms in individuals with RYR1-RM and to analyze treatment 
effects. Thus, individual and collective viewpoints were 
addressed. This design has previously been implemented 
in HRQoL and neuromuscular disorders (NMD) research 
[35–37] as well as in symptoms research [38]. Qualitative 
data were used to assess the importance and depth of com-
ments from the participants. Then data transformation was 
applied to obtain quantitative results. In this standard proce-
dure of mixed-methods research, investigators take the quali-
tative themes or codes and count them to form quantitative 
measures [34, 39]. Therefore, data transformation was used 
to measure the frequency with which each area of interest 
was mentioned by participants.
2.3  Study Goals
The primary goal of this study was to characterize symptoms 
in individuals with RYR1-RM to inform future research. 
As a secondary goal, this study aimed to analyze positive 
and negative sentiments regarding symptoms and treat-
ment effects post NAC administration in individuals with 
RYR1-RM.
2.4  Research Questions and Hypotheses
The research questions and hypotheses were as follows:
Q1: What are the major symptoms in individuals affected 
with RYR1-RM?
Q2: How do these symptoms impact individuals affected 
with RYR1-RM pre- and post-NAC administration?
We hypothesized that data transformation would identify 
a greater number of positive comments in individuals with 
RYR1-RM for postintervention interviews compared with 
baseline and preintervention interviews and that NAC group 
participants would mention more positive comments than 
placebo group participants regarding treatment effect.
2.5  Participants
Overall, 150 individuals were screened for participation in 
this study, 53 of whom were eligible and enrolled (Fig. 1). 
Of these, 47 participants completed at least one interview 
that we were able to include in the qualitative analysis. 
Therefore, a criterion-i purposeful sampling approach was 
used [40]. Although 27 postintervention interviews were 
performed, the two specific questions to assess treatment 
effect were not asked in one of those interviews. Therefore, 
the number of participants available in which to assess treat-
ment effect was 26, with 13 in each arm of the study. Demo-
graphic information is presented in Table 1.
2.6  Procedures
2.6.1  Qualitative Analysis
A total of 107 semistructured interviews were conducted 
using open-ended questions [see the electronic supplemen-
tary material (ESM)]. Two postintervention questions were 
added at the final visit. Interviews were conducted between 
March 2015 and November 2017 (baseline), September 
2015 and January 2017 (preintervention), and March 2016 
and June 2017 (postintervention). Interviews had an aver-
age duration of 13 min. All interviews were conducted at 
the NIH by the principal investigator, a research nurse, or 
a research fellow. All interviews were recorded and tran-
scribed verbatim to conduct content analysis [41], applying 
a multiphase approach, open coding, and axial coding [42]. 
Content analysis usually involves converting qualitative data 
into a quantitative form through frequency counts [39]. This 
was implemented in our research design, and this procedure 
is described in Sect. 2.6.2. Three researchers analyzed an 
initial set of five interviews to identify common areas of 
interest (domains/subdomains) and to assess agreement. 
After confirming agreement, the remaining interviews were 
distributed among the researchers for analysis. Three addi-
tional meetings were conducted to discuss the inclusion of 
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new domains/subdomains until saturation was achieved [43]. 
Differences in coding were resolved through consensus and 
tighter definitions of subdomains [44]. Likewise, interpreta-
tion and selection of quotes for publication were also dis-
cussed to ensure agreement among researchers.
2.6.2  Data Transformation and Sentiment Analyses
To perform data transformation, the number of times each 
domain/subdomain was mentioned in semistructured inter-
views was counted [36]. Those counts were used to calculate 
the average and the percentage of citations for each domain/
subdomain. When necessary, percentage scores were nor-
malized to compare domains/subdomains. This procedure 
was conducted globally (i.e., analyzing all data), by domain 
(i.e., considering every identified domain independently), 
by visit (i.e., evaluating data for each visit separately), by 
treatment (i.e., analyzing treatment effect comments for 
NAC and placebo groups independently), and by partici-
pant (i.e., assessing the records provided for all participants 
individually). A word frequency analysis was also conducted 
to identify the most cited words from semistructured inter-
views [45].
To conduct sentiment analyses, all comments related to 
the identified domains/subdomains, were labeled as either 
“positive” or “negative.” In this process, reports of “no 
change” regarding treatment effect were categorized as 
negative sentiments. Very few comments were considered 
Fig. 1  Consort diagram of study flow. NAC N-acetylcysteine, RYR1 ryanodine receptor 1
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neutral (i.e., no positive nor negative sentiment) or dual 
(i.e., positive and negative sentiments at the same time). 
For this reason, numbers from sentiment analysis slightly 
differ from the original counts. To ensure the same approach 
when attributing sentiments to participants’ comments, one 
researcher conducted this task. After completing sentiment 
analysis, results were reviewed to confirm agreement among 
researchers.
Nvivo version 12.5 software (QSR International Pty Ltd., 
Doncaster, VIC, Australia) was used to perform qualitative 
research, data transformation, and sentiment analyses.
3  Results
3.1  Qualitative Analysis
Two domains were identified after conducting data analy-
sis: symptoms and postintervention. Twelve subdomains 
comprised the symptoms domain: fatigue, fine motor, heat 
intolerance, mobility, muscle spasms, numbness, pain, res-
piratory difficulties, rhabdomyolysis (comments related to 
the destruction of striated muscle cells or elevated levels of 
creatine kinase not directly linked to any other symptom), 
scoliosis, weakness, and compounding illness-conditions 
(impacts of other issues that were not caused by the RYR1 
mutation(s), for example, symptoms that worsened their 
QoL, such as a cold, cancer, etc.). Postintervention, the 
identified domain that assessed treatment effect, included 
two subdomains: treatment benefits and side effects. Table 2 
highlights the most representative quotes for each of these 
domains/subdomains, selected by their importance and 
depth (i.e., the best described and the most detailed ones, 
respectively), to exemplify participants’ experiences/opin-
ions. As stated, these quotes were selected through consen-
sus to ensure agreement among researchers.
3.2  Data Transformation and Sentiment Analyses
This section counts the number of comments associated 
with every analyzed domain/subdomain from qualitative 
analysis. In general, more than 1000 citations were cat-
egorized and submitted to sentiment analyses. Figure 2 
displays the results for the symptoms domain, Table 3 
provides the results for analyses by visit, Fig. 3 displays 
the results for the postintervention domain with treat-
ment analysis, and Fig. 4 presents the results for the word 
frequency analysis through a word cloud image. This 
word cloud highlighted the presence of several groups 
of terms such as “sometimes, always, usually, morning, 
summer”; “different, trying, difficult, harder, affected”; 
Table 1  Participant 
demographic information
Data are presented as N (%) or mean ± standard deviation unless otherwise indicated
NAC N-acetylcysteine
Variables Overall participants Qualitative analysis NAC group Placebo group
N 53 47 13 13
Cohort % 100 89 25 25
Sex
Female 29 (55) 27 (57) 8 (62) 7 (54)
Male 24 (45) 20 (43) 5 (38) 6 (46)
Age, years
Total 29.8 ± 17.6 29.6 ± 17.1 32.8 ± 16.3 23.8 ± 17.6

















 White 47 (89) 42 (89) 12 (92) 13 (100)
 Black 6 (11) 5 (11) 1 (8) 0 (0)
Location
 Northeast 10 (19) 10 (21) 1 (8) 3 (23)
 Southeast 9 (17) 9 (19) 5 (39) 2 (15)
 Midwest 10 (19) 5 (11) 2 (15) 0 (0)
 Southwest 4 (7 ) 4 (9 ) 2 (15) 1 (8)
 West 10 (19) 10 (21) 2 (15) 2 (15)
 Abroad 10 (19) 9 (19) 1 (8) 5 (39)
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and “physical, activity, working, playing, sports”. Those 
words described in detail when, how, and which activi-
ties were more limited for participants because of their 
symptoms.
Examples of results for analysis by participant are 
available in Figs. e-1 and e-2 in the ESM.
4  Discussion
According to our sentiment analyses, more than 80% of 
the comments made by participants while talking about 
their symptoms were related to negative experiences. This 
shows that the impact of the disease on participants regard-
ing their symptoms was mainly negative, clearly reducing 
Table 2  Transcripts from the most representative domains/subdomains
Researchers’ interpretations of participants’ interviews are labeled with domain and subdomain (e.g., Symptoms > Fatigue). To represent the 
voice of individuals affected with RYR1-RM, transcripts of participants’ comments are also displayed for each case. A reference code noting the 
deidentified case number, visit, researcher initials, Nvivo transcript reference number, and sentiment assessment follows each quote. For postint-
ervention interviews, drug assignment is also included at the end of the reference code. Pseudonyms were used to protect patient identity
NAC N-acetylcysteine, RYR1 ryanodine receptor 1-related myopathies
Symptoms > Fatigue: participants reported extreme levels of fatigue, greater than what is typically defined as tiredness and impacting them all 
day. The most commonly reported ways to minimize this effect were reducing physical activity, increasing breaks to rest and recover, using 
external support tools, and asking other people for help. Fatigue not only impacted participants’ physical performance but also restricted social 
interactions and required psychological adaptations to cope with this effect from the disease. The importance of this symptom highlighted the 
value of addressing it to reduce limitations and improve HRQoL. Additionally, the impact of fatigue was a top target when assessing treatment 
effects, reemphasizing the significance of this symptom
“Just being drained by the end of the day. Since I work full time, it’s hard to get everything done I need to do at home. Thankfully, he helps me do 
a lot of the things around the home … A lot of mornings, even when I wake up, I always have to have eight hours sleep or I just can’t function, 
but I wake up tired …” < C32VA_CCP > Ref 1-2 [Dual sentiments (positive and negative)]
Symptoms > Weakness: participants also highlighted difficulty in completing several common tasks because of a lack of strength. In addition to 
reducing their range of movements, this highlighted a need for external support to perform some actions. As before, this physical effect had 
social and psychological impacts, not only for the participants but also for their family, friends, coworkers, etc. Weakness was closely related 
to participants’ fatigue as well as mobility, reinforcing its identification as one of the most important symptoms for individuals with RYR1-RM. 
Weakness was also a top target for treatment assessment
“Not as much as the strength, I would say, because … my muscles get tired first before I get out of breath. That comes with, like, going up the 
stairs. Like, when I play sports or if I do exercise, like go to the gym, and usually, I can go further, because I’m just, my muscles are getting 
tired and getting sore rather than me being out of breath and have to catch my breath” < C26VA_ICC > Ref 2 [Negative sentiment]
Symptoms > Pain: similar to previous symptoms, pain was reported by participants with RYR1-RM as a persistent effect and revealed the impact 
and difficulty of dealing with symptoms of pain on a regular basis. Pain was described as myalgia, affecting different muscles throughout the 
body and impairing motor function in daily life activities. This symptom affected not only physical performance but also mood and mental 
wellbeing
“It’s been a little more difficult because it seems like I’m having a little more weakness and a little more pain, which keeps me from being able 
to do a little bit more than what I could do before … My legs hurt really bad at movies, where my feet don’t touch the floor … then if it’s, to go 
shopping like we used to, I can’t walk” < C17VB_MMC > Ref 1-2 [Negative sentiments]
Postintervention > Treatment benefits: several participants experienced positive effects after using NAC. The most important benefits were 
focused on fatigue and weakness. Also, some individuals affected by RYR1-RM reported reduced pain. Positive impacts were not limited to 
physical effects, providing social and psychological benefits as well. Despite the multiple benefits reported, several participants also described 
no changes in response to drug treatment. Those comments were categorized as negative sentiments
“Before January, I was taking different things—CoQ10 Ubiquinol, and that had seemed to work short-term, but this new thing that we’re on 
worked a lot better … Considerably better … now I could probably recover quicker” < C20VC_CCP > Ref 1-2 [Positive sentiments/NAC]
“Since I have been on the medicine, the pain seems to have been lessened and more tolerable, and the weakness seems to be somewhat bet-
ter. But it still exists, but it seems noticeably … since I’ve been on the medicine, I do notice that my recovery has been quicker than nor-
mal” < C17VC_MMC > Ref 1-3 [Positive sentiments/NAC]
“Not at all, I think I was on the placebo. Like, I genuinely think that I didn’t notice a single difference … I think I was expecting to have more 
endurance or something, so like going up the stairs with my friends, but I still felt exactly as weak as before. Still just as tired from my normal 
life … Yeah, it didn’t do anything” < C45VC_ICC > Ref 1-4 [Negative sentiments/placebo]
Postintervention > Side effects: the only reported observation that was possibly related to the drug (i.e., feeling extreme fatigue), because the 
others were in the placebo group, was described in conjunction with potential benefits, reporting higher energy and more strength in the same 
comment. This minimized the impact of this finding. Additionally, the remaining two side effects reported by participants were assessed as not 
serious (i.e., acid reflux and headaches)
“I did have two really extreme points in the last 6 months where I had extreme fatigue and I don’t know if it’s just because it was the weather 
change or if it was the drug or what, and then I’ve had a shift where I’ve had less fatigue for a couple weeks, too.” < C01VC_CCP > Ref 1 
[Dual sentiment (positive and negative)/NAC]
“From the medicine I had? Headaches” < C24VC_ICC > Ref 1 [Negative sentiment/placebo]
“Some acid reflux” < C34VC_MMC > Ref 1 [Negative sentiment/placebo]
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their HRQoL [46, 47]. However, when considering only 
the postintervention domain, there was a shift in this trend, 
displaying 62.1% of positive comments. This trend was 
more noticeable in the NAC group (39.0% positive vs. 
14.9% negative) than in the placebo group (23.1% positive 
vs. 23.0% negative). The analysis by visit reinforced these 
results, showing higher positive and lower negative percent-
ages of comments for postintervention interviews compared 
with baseline and preintervention. Additionally, the analysis 
by participant and treatment on postintervention domain, 
revealed that 7 of 13 participants from the NAC group reg-
istered more positive than negative comments, of which six 
reported only one or no positive comments in baseline and 
preintervention interviews. Regarding the placebo group, 
only 4 of 13 participants displayed more positive than nega-
tive comments for postintervention domain, suggesting 
little positive effect on this group. Those positive reports 
maybe due to the placebo effect, which was recently stud-
ied in NMD [48, 49]. Together, qualitative and data trans-
formation results suggested a positive trend regarding the 
effect of NAC in this context. However, as with the 6-minute 
walk test, this did not reach statistical significance [20]. We 
should note that participant responses may be biased by pos-
itivity and/or social desirability because a study was being 
done in their rare disease and they felt supported. However, 
it is important to emphasize that positive comments tripled 
in number at the postintervention visit compared with the 
baseline and preintervention visits.
Based on our qualitative analysis, the most important 
symptom for individuals with RYR1-RM was fatigue, which 
is in agreement with documented clinical manifestations of 
this disease [23, 25, 50]. Data transformation revealed that 
fatigue was the most cited symptom, representing more than 
40% of the total count, which highlighted its importance 
and agrees with participant reports. The analysis by visit 
strengthened these findings, revealing consistent results 
compared with the rest of the data. Specifically, fatigue was 
the most cited symptom in all visits and displayed similar 
percentages of positive (approaching to 7%) and negative 
(approximately 35%) statements for baseline and preinter-
vention interviews. On the other hand, on postintervention 
visit, positive comments tripled in number, whereas negative 
comments decreased below 30%. Finally, the word frequency 
analysis exposed the value of terms such as “fatigue/d, stam-
ina, endurance, active, energy, breaks, exhausted, tiredness,” 
reemphasizing the importance of fatigue as a symptom for 
individuals with RYR1-RM.
Regarding weakness, qualitative analysis revealed this 
symptom was of secondary importance to participants, 
which was consistent with previous RYR1-RM research 
[23, 25, 27, 29, 50–54]. Although weakness was men-
tioned half as many times as fatigue, data transformation 
yielded approximately 200 quotes suggesting that this too 
was of high importance to participants. The analysis by 
visit showed a balanced percentage of negative experi-
ences for all visits (around 16.5%). However, positive 
statements increased from baseline and preintervention 
compared with postintervention interviews (from 1.5% and 
0.8% to 8%). Also, weakness registered in 3.4% of 18.9% 
of all positive comments, suggesting that NAC may have 
also improved strength in participants. Additionally, the 
word cloud revealed the importance of several words such 
as “muscle, pushing, strength, weakness, stairs, support, 
Fig. 2  Data transformation 
results for symptoms domain 
(N = 107). Total count of men-
tions (whole bar) with green 
reflecting positive comments 
and red reflecting negative 
comments. A + indicates 
positive comments average per 
person, D + indicates overall 
positive comments percentage 
for this domain, A − indicates 
negative comments average per 
person, D − indicates negative 
comments percentage for this 
domain, SD + indicates positive 
comments percentage for each 
subdomain, and SD − indicates 
negative comments percentage 
for each subdomain
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problem, trouble,” highlighting the significance of weak-
ness for participants.
Based on qualitative analysis, pain and mobility were on 
a third level of importance to patients, after other symp-
toms. They were closely linked to fatigue and weakness as 
antecedents. Both symptoms produced limitations on motor 
function and impacted additional areas (i.e., social, psycho-
logical, etc.). As before, there is precedence for pain and 
impaired mobility in affected individuals with RYR1-RM 
[23–27]. Although pain was cited more times than mobility 
in the data transformation analysis (131 vs. 91), mobility 
was also described with great detail in qualitative inter-
views. The analysis by visit displayed a weak trend of more 
positive and fewer negative comments in postintervention 
interviews for mobility. No clear pattern was discernable 
for pain. This finding supported the idea that NAC had lit-
tle direct effect on pain and mobility, which is consistent 
with the fact that these are not indications for NAC therapy 
[55]. Based on qualitative data, we considered that positive 
comments regarding pain and mobility in postintervention 
interviews may be due to improvements in fatigue and weak-
ness. Finally, the word frequency analysis displayed several 
terms such as “lifting, sitting, climbing walking, running, 
upstairs, elevator, and wheelchair” that stressed the value of 
addressing impaired mobility for this population.
The remaining symptoms, fine motor, heat intolerance, 
muscle spasms, numbness, respiratory difficulties, rhabdo-
myolysis, scoliosis, and compounding illness-conditions, 
captured minimal attention in qualitative analysis. They 
were described as hand dexterity problems, malignant 
hyperthermia incidents, nonvoluntary muscular contrac-
tions, insensitivity feelings, breathing insufficiency, ele-
vated levels of creatine kinase, abnormal curvatures of 
the spine, and additional limitations, all of which were 
previously reported in RYR1-RM research [23, 25, 27, 29, 
51–54, 56, 57]. Compared with fatigue (420), weakness 
(194), pain (131), and mobility (91), the remining symp-
toms were clearly less cited: compounding illness-condi-
tions (40), respiratory difficulties (23), heat intolerance 
Fig. 3  Data transformation results for postintervention domain with 
treatment analysis (N = 26). Total count of mentions (whole bar) 
with green reflecting positive comments and red reflecting nega-
tive comments, A + indicates positive comments average per person, 
D + indicates overall positive comments percentage for this domain, 
A − indicates negative comments average per person, D − indicates 
overall negative comments percentage for this domain, SD + indicates 
positive comments percentage for each subdomain and group, and SD 
− indicates negative comments percentage for each subdomain and 
group. NAC N-acetylcysteine
Fig. 4  Word cloud summarizing word frequency analysis (N = 107). 
Larger font sizes indicate a higher frequency of mentions, smaller 
font sizes a lower frequency
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(22), fine motor (18), muscle spasms (9), scoliosis (6), 
rhabdomyolysis (6), and numbness (2). To put this in 
perspective, all positive and negative citations regarding 
these symptoms represented just 13% of mentions for the 
whole study, suggesting very little impact regarding those 
symptoms. In the analysis by visit, respiratory difficul-
ties, fine motor, muscle spasms, and compounding illness-
conditions displayed a trend of more positive and fewer 
negative quotes for postintervention interviews. However, 
the number of comments was very low. Altogether, these 
findings suggest that these symptoms were linked to indi-
vidual cases in very few participants. Whilst prior stud-
ies stressed the importance of rhabdomyolysis in RYR1-
RM [24, 56, 57], our data transformation and qualitative 
results yielded little impact in this symptom. However, 
it is probable that rhabdomyolysis involvement was also 
reported by participants within the weakness symptom. 
Also, rhabdomyolysis may be a more important symptom 
in the absence of having myopathy, and having myopathy 
was an inclusion criterion in this research.
Regarding the treatment effect assessment, our quali-
tative analysis describes that any treatment benefits from 
NAC were directly linked to reducing fatigue and increasing 
strength. In addition, some indirect improvements were also 
accounted for with pain and mobility. On the other hand, 
only three side effects were identified throughout the entire 
study.
Additionally, the analysis by visit displayed a higher num-
ber of quotes for baseline interviews. However, considering 
the ratio of participants’ comments for each visit, postint-
ervention interviews provided more comments by partici-
pant, which may be due to participants’ positive expectations 
regarding the clinical trial [58]. The analysis by participant 
displayed consistent results compared with global analysis 
(i.e., analyzing all data), showing similar trends of results 
for most of the participants.
The main limitation in this study was the small sample 
size. Additionally, the context in which questions were 
asked may have shaped participants’ responses. Also, 
because affected individuals report fatigue as one of the 
more pervasive symptoms, and preclinical data suggested 
that NAC may impact fatigue, several open-ended ques-
tions requested information regarding this symptom spe-
cifically. This may have increased the number of mentions 
for fatigue. In addition, data transformation may have con-
tributed to a loss in depth of data, reducing qualitative data 
to a binary or frequency. Another limitation may be that all 
enrolled participants were ambulatory and thus were not 
representative across the RYR1-RM population.
5  Conclusion
Our qualitative analysis provides relevant information 
regarding the major symptoms in individuals with RYR1-
RM and how those symptoms influence their HRQoL. 
Data transformation analysis reported a greater number 
of positive comments in postintervention interviews than 
in baseline and preintervention visits and that NAC group 
participants contributed more positive comments regarding 
treatment effect than did the placebo group. Our findings, 
especially the identification of fatigue and weakness as key 
symptoms, the positive effect trend on those symptoms 
due to NAC treatment, and the description of participants’ 
experiences regarding their symptoms, will inform future 
studies in this rare disease. In addition, given the FDA’s 
guidance and prioritization on the inclusion of feedback 
from affected individuals in clinical trials, PRO measures, 
and drug development [18], the proposed approach is an 
excellent design for patient involvement in a clinical trial.
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